Selling Amylyx Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Selling Amylyx Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) value has fallen 16% in the last week, but insiders who sold US$765k worth of stock over the last year have had less success. Insiders would probably have been better off holding on to their shares given that the average selling price of US$8.10 is still lower than the current share price.
Amylyx製藥公司(納斯達克:AMLX)的價值在過去一週下降了16%。但在過去一年中,出售價值76.5萬美元股票的內部人士卻未能獲得成功。考慮到平均售價爲8.10美元,仍低於當前股價,內部人士可能更應該持有他們的股份。
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
儘管在長期投資中內部交易並不是最重要的事情,但從邏輯上講,您應該關注內部人員是否買入或出售股票。
Amylyx Pharmaceuticals Insider Transactions Over The Last Year
過去一年Amylyx製藥內部交易
In the last twelve months, the biggest single purchase by an insider was when Independent Chairman of the Board George Milne bought US$220k worth of shares at a price of US$2.20 per share. We do like to see buying, but this purchase was made at well below the current price of US$4.51. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
在過去12個月中,內部人士最大的一筆單獨購買是在獨立董事長George Milne以每股2.20美元的價格購買了價值22萬美元的股份。我們喜歡看到購買,但這筆交易是以遠低於當前4.51美元的價格進行的。由於是在較低的估值下進行的,這並不能告訴我們內部人士是否會覺得今天的價格有吸引力。
Happily, we note that in the last year insiders paid US$497k for 199.00k shares. But they sold 94.40k shares for US$765k. All up, insiders sold more shares in Amylyx Pharmaceuticals than they bought, over the last year. They sold for an average price of about US$8.10. We are not joyful about insider selling. However, we do note that the average sale price was significantly higher than the current share price (which is US$4.51). The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
令人高興的是,我們注意到,在過去一年中,內部人士爲199,000股支付了49.7萬美元。但他們以76.5萬美元出售了94,400股。在過去一年中,內部人士出售的Amylyx製藥股票數量超過了購買的股份數。他們的平均售價約爲8.10美元。我們對內部人士的賣出並不感到愉快。然而,我們注意到,平均銷售價格顯著高於當前的股價(4.51美元)。下面的圖表顯示了過去一年中內部交易的情況(按公司和個人)。如果你想準確知道是誰在什麼時間以多少錢出售的,只需點擊下面的圖表!
If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.
如果你和我一樣,那麼你一定不想錯過這份免費的關於小盤股票的名單,這些股票不僅被內部人買入,而且估值也很有吸引力。
Insiders At Amylyx Pharmaceuticals Have Sold Stock Recently
Amylyx製藥公司的內部人最近出售了股票
Over the last three months, we've seen notably more insider selling, than insider buying, at Amylyx Pharmaceuticals. In that time, insiders dumped US$213k worth of shares. Meanwhile Chief Financial Officer James Frates bought US$101k worth. Since the selling really does outweigh the buying, we'd say that these transactions may suggest that some insiders feel the company has been fully valued in recent months.
在過去三個月裏,我們注意到Amylyx製藥公司的內部人出售的股票顯著多於購買。期間,內部人出售了價值21.3萬美元的股份。與此同時,首席財務官詹姆斯·弗拉特斯購買了價值10.1萬美元的股份。由於出售顯然超出了購買,我們認爲這些交易可能暗示一些內部人感到公司在最近幾個月已達到完全估值。
Insider Ownership
內部持股
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that Amylyx Pharmaceuticals insiders own 10% of the company, worth about US$34m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
我喜歡觀察公司內部人士持有多少股份,以幫助我判斷他們與公司的利益連接程度。我認爲,如果內部人士在公司中持有大量股份,這是一個好兆頭。根據資料顯示,Amylyx製藥公司的內部人士持有公司10%的股份,價值約爲3400萬美元。這一內部持股比例雖然不錯,但還不算特別突出。這確實表明了合理的利益一致性。
So What Does This Data Suggest About Amylyx Pharmaceuticals Insiders?
那麼,這些數據對Amylyx製藥公司的內部人士意味着什麼呢?
Unfortunately, there has been more insider selling of Amylyx Pharmaceuticals stock, than buying, in the last three months. And our longer term analysis of insider transactions didn't bring confidence, either. Insiders own shares, but we're still pretty cautious, given the history of sales. We're in no rush to buy! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. At Simply Wall St, we found 3 warning signs for Amylyx Pharmaceuticals that deserve your attention before buying any shares.
不幸的是,在過去三個月,Amylyx製藥公司的內部人士賣出的股票數量超過了買入的數量。而我們對內部交易的長期分析也沒有帶來信心。內部人士確實持有股份,但鑑於歷史銷售記錄,我們仍然相當謹慎。我們沒有急於買入!因此,雖然了解內部人士的買賣動向是有幫助的,但了解某家公司面臨的風險同樣重要。在Simply Wall St,我們發現Amylyx製藥公司有三個警示信號,值得您在購買任何股份之前關注。
But note: Amylyx Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但請注意:Amylyx製藥公司可能不是最佳購買的股票。因此請查看這份免費的有趣公司列表,這些公司具有高ROE和低債務。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
在本文中,內部人士是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall St的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均沒有持倉。